About Us
Company Profile
company profiles
Changzhou Qianhong Biopharma Co.,Ltd. is a leading manufacturer and distributor of polysaccharide and protease drugs in the domestic biochemical pharmaceutical industry, a national high-tech enterprise and a key backbone enterprise of the national three-drug base, and has won the title of national and provincial and municipal drug quality integrity demonstration enterprise for many years. On February 18, 2011, it was successfully listed on the Shenzhen Stock Exchange. At present, it has four holding subsidiaries: ZonHon Biopharma Institute, Inc. (hereinafter referred to as ZonhonBio), Le Sun Pharmaceuticals Ltd. (hereinafter referred to as Le Sun), Qianhong Healthcare Co., Ltd. (hereinafter referred to as Qianhong Healthcare) and Hubei Runhong Biological Technology Co., Ltd. (hereinafter referred to as Hubei Runhong). | |
Our main products include kallidinogenase series, heparin sodium and low molecular weight heparin series, compound digestive enzyme preparations and asparaginase series, which are pioneered in China. The production technology and quality level have reached the international and domestic advanced level. Multiple products have passed the quality certification organized by the governments of the United States, the European Union, Japan and other countries, respectively. The company has established a perfect domestic and foreign marketing network, products spread throughout more than twenty provinces and cities across the country, and exported to Europe, USA and Japan and other international markets. The company has established Changzhou Qianhong International Biomedical Innovative Drug Incubation Base, has an advanced R & D platform in the industry, has successively made significant progress in the research on multiple recombinant protein drugs and targeted anti-tumor drugs, and has entered human clinical trials with multiple Class I new drugs; at the same time, it has also undertaken a number of national, provincial and ministerial major scientific and technological R & D projects, providing a strong core competitiveness for the development and growth of the company. Looking forward to the future, the company will adhere to the development strategy of "focusing on the field of biomedicine, guiding core competitiveness with innovative drugs, and deepening the domestic preparation market and the export of high-value-added varieties" and strive to become one of the first-class competitive large-scale biomedical enterprises in China. |
Company Profile
company profiles
Changzhou Qianhong Biopharma Co.,Ltd. is a leading manufacturer and distributor of polysaccharide and protease drugs in the domestic biochemical pharmaceutical industry, a national high-tech enterprise and a key backbone enterprise of the national three-drug base, and has won the title of national and provincial and municipal drug quality integrity demonstration enterprise for many years. On February 18, 2011, it was successfully listed on the Shenzhen Stock Exchange. At present, it has four holding subsidiaries: ZonHon Biopharma Institute, Inc. (hereinafter referred to as ZonhonBio), Le Sun Pharmaceuticals Ltd. (hereinafter referred to as Le Sun), Qianhong Healthcare Co., Ltd. (hereinafter referred to as Qianhong Healthcare) and Hubei Runhong Biological Technology Co., Ltd. (hereinafter referred to as Hubei Runhong). | |
Our main products include kallidinogenase series, heparin sodium and low molecular weight heparin series, compound digestive enzyme preparations and asparaginase series, which are pioneered in China. The production technology and quality level have reached the international and domestic advanced level. Multiple products have passed the quality certification organized by the governments of the United States, the European Union, Japan and other countries, respectively. The company has established a perfect domestic and foreign marketing network, products spread throughout more than twenty provinces and cities across the country, and exported to Europe, USA and Japan and other international markets. The company has established Changzhou Qianhong International Biomedical Innovative Drug Incubation Base, has an advanced R & D platform in the industry, has successively made significant progress in the research on multiple recombinant protein drugs and targeted anti-tumor drugs, and has entered human clinical trials with multiple Class I new drugs; at the same time, it has also undertaken a number of national, provincial and ministerial major scientific and technological R & D projects, providing a strong core competitiveness for the development and growth of the company. Looking forward to the future, the company will adhere to the development strategy of "focusing on the field of biomedicine, guiding core competitiveness with innovative drugs, and deepening the domestic preparation market and the export of high-value-added varieties" and strive to become one of the first-class competitive large-scale biomedical enterprises in China. |
